Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Neutral

Standard Deviation

Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Buy

Wall Street Data Solutions Rating

Neutral

B

Sangamo Therapeutics, Inc. Common Stock (SGMO)

Biological Products, (no Disgnostic Substances)

https://www.sangamo.com

Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.

7000 MARINA BLVD
BRISBANE, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

04/06/2000

Market Cap

187,732,054

Shares Outstanding

177,350,000

Weighted SO

177,346,980

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

EDIT --.--%

NTLA --.--%

BLUE --.--%

ALNY --.--%

IMGN --.--%

Beta

1.2310

Last Div

0.0000

Range

0.29-1.48

Chg

0.0116

Avg Vol

14024558

Mkt Cap

187732054

Exch

NASDAQ

Country

US

Phone

510 970 6000

DCF Diff

1.2573

DCF

4.8373

Div Yield

0.0000

P/S

15.2914

EV Multiple

-1.2560

P/FV

7.7618

Div Yield %

0.0000

P/E

-0.7365

PEG

-0.0434

Payout

0.0000

Current Ratio

1.0274

Quick Ratio

1.0274

Cash Ratio

0.7124

DSO

17.2734

DIO

0.0000

Op Cycle

17.2734

DPO

364.9585

CCC

-347.6851

Gross Margin

-0.4329

Op Margin

-20.2156

Pretax Margin

-20.2416

Net Margin

-20.3369

Eff Tax Rate

-0.0047

ROA

-2.6843

ROE

-3.3492

ROCE

-4.5953

NI/EBT

1.0047

EBT/EBIT

1.0013

EBIT/Rev

-20.2156

Debt Ratio

0.3128

D/E

1.2282

LT Debt/Cap

0.5512

Total Debt/Cap

0.5512

Int Coverage

2.1800

CF/Debt

-5.9586

Equity Multi

3.9263

Rec Turnover

21.1308

Pay Turnover

1.0001

Inv Turnover

0.0000

FA Turnover

0.3125

Asset Turnover

0.1320

OCF/Share

-0.8501

FCF/Share

-0.8767

Cash/Share

0.6699

OCF/Sales

-14.1222

FCF/OCF

1.0312

CF Coverage

-5.9586

ST Coverage

0.0000

CapEx Coverage

-32.0181

Div&CapEx Cov

-32.0181

P/BV

7.7618

P/B

7.7618

P/S

15.2914

P/E

-0.7365

P/FCF

-1.0500

P/OCF

-1.0606

P/CF

-1.0606

PEG

-0.0434

P/S

15.2914

EV Multiple

-1.2560

P/FV

7.7618

DPS

0.0000

Latest Headlines (EST)

Investing.com Jan 09, 14:06 2 Low-Priced Gene Therapy Stocks to Speculate On Benzinga Nov 06, 10:00 What 8 Analyst Ratings Have To Say About Sangamo Therapeutics Benzinga Nov 03, 13:00 What To Know About RBC Capital's Downgrade of Sangamo Therapeutics

Revenue Product Segmentation

License

$48.68M

Service

$1.32M

License $48.68M (97.36%)Service $1.32M (2.64%)License: $48.68M (97.36%)License $48,679,000Service: $1.32M (2.64%)Service $1,321,000Total: $50.00M Total $50,000,000
a